Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation, a Novel Approach for the Differentiation and Expansion of Induced Pluripotent Stem Cells to Generate Cytotoxic Innate Lymphocytes
28 juil. 2022 16h00 HE
|
Umoja Biopharma, Inc.
New data demonstrates Umoja’s synthetic receptor enabled differentiation (ShRED™) as a novel platform to differentiate and expand progenitor cells and cytotoxic innate lymphocytes using the RACRTM...
Umoja Biopharma Announces Participation in Upcoming Scientific Summits
30 juin 2022 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...
Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual Meeting
16 juin 2022 08h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, June 16, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...
Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology
10 juin 2022 10h30 HE
|
Umoja Biopharma, Inc.
SEATTLE and PESSAC, France, June 10, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat...
Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer
23 mai 2022 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE and DALLAS, May 23, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for...
Umoja Biopharma Presents New Preclinical Data at ASGCT 2022 Annual Meeting on its VivoVec Platform Describing Preclinical Safety Data for UB-VV100 Product Candidate, VivoVec Engineering for Improved in vivo CAR T cell Generation and Development of a Scalable Manufacturing Platform
19 mai 2022 08h00 HE
|
Umoja Biopharma, Inc.
UB-VV100 preclinical safety data demonstrates overall low risk for off target transduction and has a favorable safety and biodistribution profile Next generation VivoVec surface engineering promotes...
Umoja Biopharma Announces Resignation of Board Chair Clay B. Siegall
11 mai 2022 16h36 HE
|
Umoja Biopharma, Inc.
Resignation effective immediatelyCEO Scharenberg assumes the role of interim Board Chair SEATTLE, May 11, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. announced today Clay B. Siegall, Ph.D....
Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022
04 mai 2022 10h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells
03 mai 2022 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
Umoja Biopharma to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting
02 mai 2022 16h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...